8-K: Silexion Therapeutics Faces Nasdaq Delisting

Silexion Therapeutics Corp received a delisting notice from Nasdaq due to non-compliance with minimum shareholders equity requirements, and intends to appeal.

Summary

• Silexion Therapeutics Corp received a delisting notice from Nasdaq on August 18, 2026, for failing to meet the minimum shareholders equity requirement of $2,500,000 for continued listing on The Nasdaq Capital Market.
• The company's shareholders equity was reported as $44,000 as of June 30, 2026, and it does not currently meet any alternative listing standards.
• Silexion Therapeutics intends to request an appeal of the delisting determination before a Nasdaq Hearings Panel by August 25, 2026.
• The company is currently under a Mandatory Hearings Panel Monitor due to a prior decision, which restricts Nasdaq from granting additional time to regain compliance.
• If the appeal is unsuccessful, trading of Silexion's ordinary shares and warrants will be suspended, and a Form 25-NSE will be filed to remove them from Nasdaq.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the delisting notice, indicating significant financial distress and potential loss of exchange listing.

Positives

• The company intends to appeal the delisting notice, indicating a proactive approach to resolving the issue.
• The company plans to present evidence of steps taken and to be taken to restore and maintain compliance with the shareholders equity requirement during the appeal.

Negatives

• Received a delisting notice from Nasdaq due to non-compliance with the minimum shareholders equity requirement ($2,500,000).
• Shareholders equity was only $44,000 as of June 30, 2026, and the company does not meet alternative listing standards.
• The company is subject to a Mandatory Hearings Panel Monitor, preventing Nasdaq from granting additional time to regain compliance.
• Potential suspension of trading and removal from Nasdaq if the appeal is unsuccessful.

Risks

• The company may not be successful in its appeal of the Nasdaq delisting determination.
• The Nasdaq Hearings Panel may not grant additional time to achieve or maintain the required shareholders equity.
• Suspension of trading and delisting from The Nasdaq Capital Market if the appeal fails.
• Filing of Form 25-NSE with the SEC to remove securities from listing on Nasdaq.
• Potential for significant negative impact on share price and liquidity if delisted.

Future Outlook

The company's future outlook is uncertain and heavily dependent on the success of its appeal to Nasdaq. If the appeal fails, trading will be suspended, and securities will be delisted. The company states there is no assurance that the appeal will be successful or that additional time will be granted.

Management Comments

• The Company intends to request an appeal of the determination before a Nasdaq Hearings Panel in a timely manner.
• As part of our strategy for our appeal, we intend to present to the Panel evidence that we have taken steps and will continue to take steps to restore and maintain compliance with the shareholders equity requirement.
• There can be no assurance, however, that our appeal will be successful or that the Panel will grant us any additional time to regain compliance with that requirement.

Industry Context

StockSavvy.ai notes that Nasdaq listing standards are crucial for maintaining liquidity and investor confidence. Failure to meet these standards, particularly equity requirements, often signals significant financial distress and can lead to a loss of market access, impacting a company's ability to raise capital and its valuation.

Stakeholder Impact

• Shareholders: Potential for suspension of trading and delisting, leading to reduced liquidity and significant loss in investment value.
• Creditors: Increased risk of default if the company cannot maintain its listing or access capital markets.
• Employees: Uncertainty regarding job security and company stability.

Next Steps

• Request an appeal of the delisting determination before a Nasdaq Hearings Panel by August 25, 2026.
• Present evidence to the Panel regarding steps taken to restore and maintain shareholders equity compliance.
• Await the decision of the Nasdaq Hearings Panel regarding the appeal.

Key Dates

Recommendation

The delisting notice from Nasdaq due to critically low shareholders equity is a severe negative indicator. The company's appeal is uncertain, and the prior monitor status limits options. This situation poses a significant risk to liquidity and valuation, making it a strong sell.

Keywords

delisting, Nasdaq, shareholders equity, listing deficiency, appeal, Silexion Therapeutics, compliance